Results 161 to 170 of about 12,086 (222)
Some of the next articles are maybe not open access.
Thrombosis and Haemostasis, 2005
SummaryThrombolytic agents are plasminogen activators that convert the zymogen plasminogen to the active enzyme plasmin, which degrades fibrin. Elucidation of the molecular mechanism of physiological fibrinolysis opened up a new era of fibrin-specific thrombolysis.
Désiré, Collen, H Roger, Lijnen
openaire +2 more sources
SummaryThrombolytic agents are plasminogen activators that convert the zymogen plasminogen to the active enzyme plasmin, which degrades fibrin. Elucidation of the molecular mechanism of physiological fibrinolysis opened up a new era of fibrin-specific thrombolysis.
Désiré, Collen, H Roger, Lijnen
openaire +2 more sources
Cardiovascular Drugs and Therapy, 1994
The fibrinolytic system comprises an inactive pro-enzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, that degrades fibrin. Two immunologically distinct plasminogen activators have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Plasminogen activation
M, Verstraete, H R, Lijnen
openaire +2 more sources
The fibrinolytic system comprises an inactive pro-enzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, that degrades fibrin. Two immunologically distinct plasminogen activators have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Plasminogen activation
M, Verstraete, H R, Lijnen
openaire +2 more sources
Thrombolytic Agents: A Perspective
Annals of Internal Medicine, 1968Excerpt The feasibility of dissolving intravascular fibrin deposits by enzymatic means (thrombolysis) appears established, and the prospect of clinical use of this method has stimulated efforts to ...
E, Genton, L, Pechet
openaire +2 more sources
Development of thrombolytic agents
Biotechnology Advances, 1993Despite their widespread use in patients with acute myocardial infarction, all currently available thrombolytic agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications.
H R, Lijnen, D, Collen
openaire +2 more sources
Thrombolytic Agents in Development
Drugs, 1995The quest continues for thrombolytic agents with a higher thrombolytic potency, specific thrombolytic activity and/or a better fibrin selectivity. Several lines of research towards improvement of thrombolytic agents are being explored, including the construction of mutants and variants of plasminogen activators (PAs), chimaeric PAs, conjugates of PAs ...
M, Verstraete, H R, Lijnen, D, Collen
openaire +2 more sources
Hemodialysis International, 2000
Thrombus dissolution is dependent on activators of plasminogen, the principal enzyme of fibrinolysis, reaching plasminogen bound to the surface of fibrin, and overcoming the many inhibitors of clot lysis present in the plasma milieu. In dialysis patients with occluded catheters and grafts, three activators — streptokinase, urokinase, and tissue ...
openaire +2 more sources
Thrombus dissolution is dependent on activators of plasminogen, the principal enzyme of fibrinolysis, reaching plasminogen bound to the surface of fibrin, and overcoming the many inhibitors of clot lysis present in the plasma milieu. In dialysis patients with occluded catheters and grafts, three activators — streptokinase, urokinase, and tissue ...
openaire +2 more sources
An Overview of Thrombolytic Agents
Chest, 1990The use of thrombolytic therapy has increased considerably in the past five years, particularly in patients with acute myocardial infarction. The agents that have been used in humans thus far include streptokinase and urokinase, as well as tissue-type plasminogen activator and, most recently, single-chain urokinase-type plasminogen activator or pro ...
openaire +2 more sources
Thrombolytic agents and anticoagulants
Cardiovascular Drugs and Therapy, 1993The medical and scientific communities, appreciating the pivotal role of thrombosis in the evolution and expression of atherosclerotic coronary artery disease, have embarked upon intense efforts to develop safe, effective, and affordable thrombolytic agents and anticoagulants.
openaire +2 more sources
Evaluation of Thrombolytic Agents
Drugs, 1997The mechanism of action of currently available thrombolytic agents, such as streptokinase, urokinase, alteplase (recombinant tissue-type plasminogen activator; rt-PA) and anistreplase (anisoylated plasminogen streptokinase activator complex; APSAC), involves conversion of inactive plasminogen to plasmin, a potent fibrinolytic.
openaire +2 more sources